Investors and Media
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing tilsotolimod, a Toll-like receptor (TLR) 9 agonist for the treatment of certain cancers. Tilsotolimod is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera is also focused on the acquisition, development and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs..
Mar 12, 2020
Mar 05, 2020
Jan 14, 2020
Copyright West LLC. Minimum 15 minutes delayed.